News Snapshot:
Japan has promising biotech startups that often lack the support needed to bring their technology to market. (Photo courtesy of Chordia Therapeutics) SHOTA UEHARA, Nikkei staff writer May 21, 2022 00:33 JST | U.S. Copy Copied TOKYO -- U.S.-based Arch Venture Partners has launched a $3 billion venture capital fund specializing in medical technologies, one of the world's largest, with Japanese startups among its potential targets. Read Next
